Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Cold Atmospheric Plasma (CAP) is an emerging technology with great potential for biomedical applications such as sterilizing equipment and antitumor strategies. CAP has also been shown to improve skin wound healing in vivo, but the biological mechanisms involved are not well known. Our study assessed a possible effect of a direct helium jet CAP treatment on keratinocytes, in both the immortalized N/TERT-1 human cell line and primary keratinocytes obtained from human skin samples. The cells were covered with 200 µL of phosphate buffered saline and exposed to the helium plasma jet for 10–120 s. In our experimental conditions, micromolar concentrations of hydrogen peroxide, nitrite and nitrate were produced. We showed that long-time CAP treatments (≥60 s) were cytotoxic, reduced keratinocyte migration, upregulated the expression of heat shock protein 27 (HSP27) and induced oxidative cell stress. In contrast, short-term CAP treatments (<60 s) were not cytotoxic, did not affect keratinocyte proliferation and differentiation, and did not induce any changes in mitochondria, but they did accelerate wound closure in vitro by improving keratinocyte migration. In conclusion, these results suggest that helium-based CAP treatments improve wound healing by stimulating keratinocyte migration. The study confirms that CAP could be a novel therapeutic method to treat recalcitrant wounds.

Details

Title
Cold Atmospheric Plasma Jet Treatment Improves Human Keratinocyte Migration and Wound Closure Capacity without Causing Cellular Oxidative Stress
Author
Marches, Aurélie 1 ; Clement, Emily 2   VIAFID ORCID Logo  ; Albérola, Géraldine 3 ; Marie-Pierre Rols 3   VIAFID ORCID Logo  ; Cousty, Sarah 4 ; Simon, Michel 2   VIAFID ORCID Logo  ; Merbahi, Nofel 5   VIAFID ORCID Logo 

 Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse University, CNRS, Inserm, Université Paul Sabatier, Place du Dr Baylac, 31059 Toulouse, France; Laboratoire des Plasmas et Conversion d’Énergie (LAPLACE), 118 Route de Narbonne, 31062 Toulouse, France 
 Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse University, CNRS, Inserm, Université Paul Sabatier, Place du Dr Baylac, 31059 Toulouse, France 
 Institut de Pharmacologie et de Biologie Structurale (IPBS), 205 Route de Narbonne, 31077 Toulouse, France 
 Laboratoire des Plasmas et Conversion d’Énergie (LAPLACE), 118 Route de Narbonne, 31062 Toulouse, France; UFR Odontologie, CHU Toulouse, 3 Chemin des Maraîchers, 31400 Toulouse, France; Département de Chirurgie et Médecine Orales, Centre Hospitalo—Universitaire de Toulouse, 3 Chemin des Maraîchers, CEDEX 9, 31059 Toulouse, France 
 Laboratoire des Plasmas et Conversion d’Énergie (LAPLACE), 118 Route de Narbonne, 31062 Toulouse, France 
First page
10650
Publication year
2022
Publication date
2022
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2716547559
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.